25 August 2014: Australian technology company Global Kinetics Corporation is leading the global charge to roll out a new mobile health technology capable of measuring Parkinson’s disease symptoms.
GKC Managing Director Mr Andrew Maxwell said his company’s lead product, the Parkinson’s KinetiGraph, is already available to over 50,000 people with Parkinson’s across Europe, Australia and Asia.
It is anticipated that PD patients in 30 nations worldwide will have access to PKG technology within 18 months. Mr Maxwell was responding to reports that global communications giant Intel is collaborating with the prestigious Michael J Fox Foundation to develop wearable gadgets to monitor patients with Parkinson’s disease.
He commented: “We are pleased that the Michael J Fox Foundation and Intel, like GKC, has recognised the opportunity for people with Parkinson’s to receive better care, when that care is informed by objective measurement.
“Our company was founded by leading Australian neurologists and brain researchers who recognised that clinicians require actionable information to inform their patient management.
“GKC has long held the view that measurement matters in Parkinson’s disease, and this will allow clinicians to provide optimum treatment, leading to better quality of life for patients and superior health cost outcomes”
“Working from our base in Australia we have recruited many of the premier movement disorder treatment centres in Europe and Australasia. We are working with key patient advocacy groups across Europe, in the UK and Australia.”
“The US is our next frontier, we expect FDA approval shortly and we are looking forward to working with US clinicians, patient advocacy groups and industry players.”
The Parkinson’s Kinetigraph, or PKG, is a wrist worn technology that automatically records highly specific movement data and medication compliance information.
“Patents are in place securing our technology in all major global markets and cover the data analysis capability allowing measurement of Parkinson’s symptoms.”
The technology has been developed by Australian neurologists at the Melbourne based Florey Institute of Neuroscience and Mental Health and is now being rolled out by Global Kinetics Corporation.
For more information on the Parkinson’s Kinetigraph please go to www.globalkineticscorporation.com.au For further Information contact Emma Power at Monsoon Communications Australia on +61 419 149 525.
About Global Kinetics Corporation
Global Kinetics Corporation (GKC) is a privately held technology company headquartered in Australia focused on globally commercialising its innovative movement disorder technology, specifically for the treatment of Parkinson’s Disease. The company’s lead product is the Parkinson’s Kinetigraph (PKG), a first in class medical technology enabling neurologists to better manage the key disabling movement symptoms of Parkinson’s.
The PKG is a wrist worn device that automatically records motion data to assist doctors in their diagnosis and treatment of symptoms. This objective movement data recorded over 6 days, is downloaded within minutes and assists doctors to analyse disease progression and treatment response. Parkinson’s disease is a progressive disorder of the brain’s frontal lobe, which controls impulsive and non-impulsive movement. An estimated 6 million people around the world are affected. The main motor (or movement) related symptoms of Parkinson’s disease are bradykinesia, rigidity, tremors and postural instability. Other non-movement symptoms may be experienced such as speech and swallowing difficulties, cognitive impairment or behavioural change and sleep disturbance.
Help employers find you! Check out all the jobs and post your resume.
